Bevacizumab plus irinotecan in patients with recurrent high grade malignant gliomas.

被引：0
|
作者：
Legaspi, Jairo
Ceniceros, Lucia
Espinos, Jaime
Valtuena, German
Martin, Patricia
Castanon Alvarez, Eduardo
Aristu, Javier
Baraibar, Iosune
Salas, Diego
Sala, Pablo
Gardeazabal, Itziar
Zubiri Oteiza, Leyre
Olarte, Alicia
Gil-Bazo, Ignacio
Dominguez, Pablo
Pablo Fusco, Juan
Isabel Martinez, Maria
Aramendia, Jose M.
Fernandez-Hidalgo, Oscar
Santisteban, Marta
机构：
[1] Univ Navarra Clin, Pamplona, Spain
[2] Univ Navarra Clin, Dept Oncol, Pamplona, Spain
[3] Univ Navarra, Dept Med Oncol, E-31080 Pamplona, Spain
[4] Univ Navarra Clin, Med Oncol 1Dept, Pamplona, Spain
[5] Univ Navarra Clin, Dept Med Oncol, Pamplona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e13057
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13057
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
    Desjardins, Annick
    Reardon, David A.
    Herndon, James E., II
    Marcello, Jennifer
    Quinn, JenniferA.
    Rich, Jeremy N.
    Sathornsumetee, Sith
    Gururangan, Sriclharan
    Sampson, John
    Bailey, Leighann
    Bigner, Darell D.
    Friedman, Allan H.
    Friedman, Henry S.
    Vredenburgh, James J.
    CLINICAL CANCER RESEARCH, 2008, 14 (21) : 7068 - 7073
  • [2] Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas
    de Groot, John F.
    Yung, Wai Kwan A. Fred
    CANCER JOURNAL, 2008, 14 (05): : 279 - 285
  • [3] A phase I trial of intravenous liposomal irinotecan in patients with recurrent high-grade gliomas.
    Clarke, Jennifer Leigh
    Molinaro, Annette M.
    DeSilva, Ashley A.
    Rabbitt, Jane E.
    Drummond, Daryl C.
    Chang, Susan Marina
    Butowski, Nicholas A.
    Prados, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
    Zuniga, R. M.
    Torcuator, R.
    Jain, R.
    Anderson, J.
    Doyle, T.
    Ellika, S.
    Schultz, L.
    Mikkelsen, T.
    JOURNAL OF NEURO-ONCOLOGY, 2009, 91 (03) : 329 - 336
  • [5] Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
    R. M. Zuniga
    R. Torcuator
    R. Jain
    J. Anderson
    T. Doyle
    S. Ellika
    L. Schultz
    T. Mikkelsen
    Journal of Neuro-Oncology, 2009, 91 : 329 - 336
  • [6] Bevacizumab for patients with recurrent high grade gliomas
    Gilbert, Mark R.
    CANCER INVESTIGATION, 2007, 25 : 1 - 1
  • [7] Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure.
    Desjardins, Annick
    Vredenburgh, James J.
    Peters, Katherine B.
    Threatt, Stevie
    Herndon, James Emmett
    Sampson, John Howard
    Friedman, Allan H.
    Friedman, Henry S.
    Reardon, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Bevacizumab plus irinotecan in treatment of recurrent brain gliomas
    Stec, Rafal
    Bodnar, Lubomir
    Smoter, Marta
    Szczylik, Cezary
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2010, 14 (04): : 253 - 258
  • [9] Combination of bevacizumab plus irinotecan in recurrent malignant gliomas (MG): A retrospective study of efficacy and safety
    Gil Gil, M. J., Sr.
    Martinez-Garcia, M.
    Reynes, G.
    Costas, E.
    Fernandez-Chacon, C.
    Pernas, S.
    Benavides, M.
    Herrero, A.
    Perez-Martin, J.
    Balana, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] FAVORABLE RESPONSES TO BIWEEKLY BEVACIZUMAB AND IRINOTECAN IN PEDIATRIC PATIENTS WITH HIGH GRADE GLIOMAS AND OTHER RECURRENT TUMORS
    Khatib, Ziad
    Sunkersett, Gauri
    PEDIATRIC BLOOD & CANCER, 2013, 60 : S75 - S75
12345